π Key Learning
- Chronic autoimmune symmetrical polyarthritis, classically affecting small joints (MCPs, PIPs, wrists) but sparing the DIPJs
- Presents with morning stiffness > 1 hour, joint swelling and pain
- Antibodies: RhF, anti-CCP
- Managed with DMARDs and bridging steroids; biologics in refractory cases
𧬠Pathophysiology
- Autoimmune synovial inflammation β joint destruction
- Progressive cartilage and bone erosion if untreated
π Clinical Features
- Peak onset: 30β50 years, Female > Male (3:1)
- HLA-DR4 association
-
Symmetrical small joint pain/swelling: MCP, PIP, wrists, MTPs
- Spares DIPJs
- Morning stiffness > 1 hour
-
Joint deformities in advanced disease:
- Boutonnière deformity
- Swan-neck deformity
- Rheumatoid nodules (extensor surfaces)
- Positive squeeze test
- Warm, boggy joints

π§ͺ Investigations
- Bloods:
- 1st line: Rheumatoid factor - positive in 7/10 people with RA
- An IgM antibody which reacts with IgG
- Prognostic marker - high RhF levels associated with progressive disease
- 2nd line: If RhF negative, measure anti-cyclic citrullinated peptide antibodies (anti-CCP)
- CRP/ESR are commonly elevated
- 1st line: Rheumatoid factor - positive in 7/10 people with RA
- XR: Juxtaarticular osteoporosis
π₯ Management of Flares
- 1st Line: Short-term treatment with steroids
- Intra-articular glucocorticoid if localised flare
- IM glucocorticoid if IA is not possible - methylprednisolone, triamcinolone
- PO glucocorticoid if not practical to give IM
- Consider offering an NSAID for short term symptomatic relief with PPI
π Long-term Management
-
1st Line: DMARD monotherapy (methotrexate, sulfasalazine, leflunomide) at diagnosis
- Methotrexate is commonly given 1st line for RA
- Consider hydroxychloroquine for palindromic rheumatism
- Consider bridging steroid when commencing DMARD
- 2nd Line: Combination of 2 DMARDs
-
3rd Line: Add biological DMARDs:
- TNF inhibitors: etanercept, infliximab, adalimumab
- Other biologics: rituximab, abatacept
π§ͺ DMARD Side Effects
DMARD | Side Effects |
---|---|
Methotrexate | Myelosuppression, liver cirrhosis, pneumonitis/fibrosis - Monitor FBC, LFTs |
Sulfasalazine | Oligospermia, Heinz body anaemia, ILD |
Leflunomide | HTN, hepatotoxicity, ILD |
Hydroxychloroquine | Retinopathy, corneal deposits |
π€° RA in Pregnancy
- Safe DMARDs: Sulfasalazine, Hydroxychloroquine (SHafe in pregnancy))
- Avoid: Methotrexate, Leflunomide
π« Extra-Articular Features
π« Respiratory
- Pulmonary fibrosis
- Pleural effusions (exudative)
- Caplan syndrome (RA + coal dust exposure)
- Pulmonary nodules
- Bronchiolitis obliterans
π Ocular
- Keratoconjunctivitis sicca (most common)
- Scleritis / episcleritis
- Corneal ulcers
β€οΈ Other
- Accelerated CV disease
- Osteoporosis
- Depression
- Felty's syndrome (RA + splenomegaly + neutropenia)
- AA amyloidosis
π Palindromic Rheumatism
- Relapsing/remitting monoarthritis (large joints)
- Tx: Hydroxychloroquine, other DMARDs if required
π Exam Clues & Clinchers
- Symmetrical small joint pain, sparing DIPJs, with stiffness > 1 hour in morning
- Antibodies: RhF +ve - if negative check anti-CCP = highly specific
- Treatment: Methotrexate is 1st line; avoid in pregnancy